Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neurogene (NGNE) Research & Development (2018 - 2025)

Historic Research & Development for Neurogene (NGNE) over the last 4 years, with Q3 2025 value amounting to $17.2 million.

  • Neurogene's Research & Development rose 587.04% to $17.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.7 million, marking a year-over-year increase of 2070.85%. This contributed to the annual value of $60.9 million for FY2024, which is 3721.9% up from last year.
  • As of Q3 2025, Neurogene's Research & Development stood at $17.2 million, which was up 587.04% from $19.4 million recorded in Q2 2025.
  • Neurogene's 5-year Research & Development high stood at $19.4 million for Q2 2025, and its period low was $10.3 million during Q1 2023.
  • Over the past 3 years, Neurogene's median Research & Development value was $15.3 million (recorded in 2024), while the average stood at $14.5 million.
  • In the last 5 years, Neurogene's Research & Development skyrocketed by 5254.34% in 2024 and then skyrocketed by 587.04% in 2025.
  • Over the past 3 years, Neurogene's Research & Development (Quarter) stood at $12.2 million in 2023, then increased by 25.96% to $15.3 million in 2024, then rose by 12.34% to $17.2 million in 2025.
  • Its Research & Development stands at $17.2 million for Q3 2025, versus $19.4 million for Q2 2025 and $17.8 million for Q1 2025.